Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Aytu Biopharma (AYTU) over the last 14 years, with Q4 2025 value amounting to $17000.0.

  • Aytu Biopharma's Capital Expenditures rose 18333.33% to $17000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $103000.0, marking a year-over-year decrease of 7813.16%. This contributed to the annual value of $228000.0 for FY2025, which is 3069.91% down from last year.
  • Latest data reveals that Aytu Biopharma reported Capital Expenditures of $17000.0 as of Q4 2025, which was up 18333.33% from $17000.0 recorded in Q2 2025.
  • Aytu Biopharma's 5-year Capital Expenditures high stood at $329000.0 for Q2 2024, and its period low was -$13.1 million during Q2 2021.
  • Over the past 3 years, Aytu Biopharma's median Capital Expenditures value was $17000.0 (recorded in 2025), while the average stood at -$1.8 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 12321.37% in 2021, then soared by 18333.33% in 2025.
  • Aytu Biopharma's Capital Expenditures (Quarter) stood at -$13.1 million in 2021, then skyrocketed by 100.05% to $6000.0 in 2024, then soared by 183.33% to $17000.0 in 2025.
  • Its Capital Expenditures stands at $17000.0 for Q4 2025, versus $17000.0 for Q2 2025 and $69000.0 for Q1 2025.